LUNG Valuation

Pulmonx Corp

Add to Watchlist

Advanced Chart

1.780

+0.05(2.890%)1D

Overview
Forecast
Valuation
Earnings

LUNG Relative Valuation

LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUNG is overvalued; if below, it's undervalued.

Historical Valuation

Pulmonx Corp (LUNG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -13.33. The fair price of Pulmonx Corp (LUNG) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：1.75

Fair

-1.21

Trailing

Forward

-0.75

EV/EBITDA

Pulmonx Corp. (LUNG) has a current EV/EBITDA of -0.75. The 5-year average EV/EBITDA is -13.92. The thresholds are as follows: Strongly Undervalued below -45.03, Undervalued between -45.03 and -29.48, Fairly Valued between 1.63 and -29.48, Overvalued between 1.63 and 17.18, and Strongly Overvalued above 17.18. The current Forward EV/EBITDA of -0.75 falls within the Historic Trend Line -Fairly Valued range.

-0.71

EV/EBIT

Pulmonx Corp. (LUNG) has a current EV/EBIT of -0.71. The 5-year average EV/EBIT is -12.18. The thresholds are as follows: Strongly Undervalued below -39.53, Undervalued between -39.53 and -25.86, Fairly Valued between 1.50 and -25.86, Overvalued between 1.50 and 15.17, and Strongly Overvalued above 15.17. The current Forward EV/EBIT of -0.71 falls within the Historic Trend Line -Fairly Valued range.

0.74

Pulmonx Corp. (LUNG) has a current PS of 0.74. The 5-year average PS is 12.15. The thresholds are as follows: Strongly Undervalued below -12.82, Undervalued between -12.82 and -0.34, Fairly Valued between 24.64 and -0.34, Overvalued between 24.64 and 37.12, and Strongly Overvalued above 37.12. The current Forward PS of 0.74 falls within the Historic Trend Line -Fairly Valued range.

-5.05

P/OCF

Pulmonx Corp. (LUNG) has a current P/OCF of -5.05. The 5-year average P/OCF is -9.25. The thresholds are as follows: Strongly Undervalued below -42.20, Undervalued between -42.20 and -25.72, Fairly Valued between 7.23 and -25.72, Overvalued between 7.23 and 23.70, and Strongly Overvalued above 23.70. The current Forward P/OCF of -5.05 falls within the Historic Trend Line -Fairly Valued range.

-2.56

P/FCF

Pulmonx Corp. (LUNG) has a current P/FCF of -2.56. The 5-year average P/FCF is -12.17. The thresholds are as follows: Strongly Undervalued below -39.95, Undervalued between -39.95 and -26.06, Fairly Valued between 1.72 and -26.06, Overvalued between 1.72 and 15.61, and Strongly Overvalued above 15.61. The current Forward P/FCF of -2.56 falls within the Historic Trend Line -Fairly Valued range.

Pulmonx Corp (LUNG) has a current Price-to-Book (P/B) ratio of 1.02. Compared to its 3-year average P/B ratio of 2.70 , the current P/B ratio is approximately -62.26% higher. Relative to its 5-year average P/B ratio of 3.75, the current P/B ratio is about -72.80% higher. Pulmonx Corp (LUNG) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.29%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -10.63% , the current FCF yield is about -100.00% lower.

1.05

P/B

Median3y

2.70

Median5y

3.75

-45.37

FCF Yield

Median3y

-15.29

Median5y

-10.63

Competitors Valuation Multiple

The average P/S ratio for LUNG's competitors is 0.00, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 14.80%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Baird Medical Investment Holdings Ltd

Performance Decomposition

Market capitalization of LUNG decreased by 71.52% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 20.78M to 23.86M.

The secondary factor is the Margin Expansion, contributed -13.76%to the performance.

Overall, the performance of LUNG in the past 1 year is driven by Revenue Growth. Which is more sustainable.

14.80%

20.78M → 23.86M

Revenue Growth

-13.76%

-73.74 → -63.59

Margin Expansion

-72.56%

-4.54 → -1.24

P/E Change

-71.52%